Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Polatuzumab Vedotin Plus Glofitamab in Relapsed or Refractory DLBCL Within 12 Months of R-CHOP
KCT0012253Phase 2Not yet recruiting
- Sponsor
- Roche
- Start
- Sep 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of polatuzumab vedotin, glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Roche. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
polatuzumab vedotinglofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on KCT0012253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012253.